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Autophagy is induced upon platelet activation and is essential for
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Key Points
• Autophagy, an essential
degradation pathway, is
constitutively active in resting
platelets and is induced upon
platelet activation.
• Platelet autophagy is
indispensable for hemostasis
and thrombus formation.
Autophagy is important for maintaining cellular homeostasis, and thus its deficiency is
implicated in a broad spectrum of human diseases. Its role in platelet function has only
recently been examined. Our biochemical and imaging studies demonstrate that the core
autophagy machinery exists in platelets, and that autophagy is constitutively active in
resting platelets. Moreover, autophagy is induced upon platelet activation, as indicated
by agonist-induced loss of the autophagy marker LC3II. Additional experiments, using
inhibitors of platelet activation, proteases, and lysosomal acidification, as well as plate-
lets fromknockoutmousestrains,showthat agonist-inducedLC3II loss is aconsequence
of platelet signaling cascades and requires proteases, acidic compartments, and mem-
brane fusion. To assess thephysiological role ofplatelet autophagy,wegenerated amouse
strain with amegakaryocyte- and platelet-specific deletion ofAtg7, an enzyme required for
LC3II production. Ex vivo analysis of platelets from these mice shows modest defects in
aggregation and granule cargo packaging. Although these mice have normal platelet numbers and size distributions, they exhibit a
robustbleedingdiathesis in the tail-bleedingassayandaprolongedocclusion time in theFeCl3-inducedcarotid injurymodel.Our results
demonstrate that autophagy occurs in platelets and is important for hemostasis and thrombosis. (Blood. 2015;126(10):1224-1233)
Introduction
Autophagy, one of the major degradation pathways in eukaryotes, is
important for cellular homeostasis and is implicated in abroad spectrum
of human diseases including cancer, neurodegeneration, and cardio-
vascular diseases.1 There are 3 main types: chaperone-mediated auto-
phagy,2 microautophagy,3,4 and the primary form, macroautophagy
(referred to hereafter as autophagy).5 Autophagy involves de novo
synthesis of double-membraned organelles called autophagosomes that
contain cytosolic constituents including damaged organelles (eg, mito-
chondria) and protein aggregates. Autophagosomes fuse with multive-
sicular bodies, late endosomes, and lysosomes to form autolysosomes,6
inwhichwaste elimination, energy production, and recycling of cellular
components take place.
Autophagosome biogenesis and maturation use several protein
complexes.7-10 In mammals, cellular signals (eg, starvation) activate
the Ulk1 complex (Ulk1, FIP200, Atg13, andAtg101),11-14 which
together with syntaxin 17,15 localizes Atg14/Atg14L16-19 to the
endoplasmic reticulum.15,20 This recruits the Beclin 1-Vps34 core
complex (Beclin 1, Vps34, and Vps15) to autophagosome initiation
sites and promotes phosphatidylinositol 3-phosphate production for
recruitment of additional autophagy pathway components.20,21 Two
ubiquitin-like conjugation systems are also important for autopha-
gosome biogenesis. One uses Atg7 and Atg10 (E1 and E2 enzymes,
respectively) to form an Atg12–Atg5 conjugation.22-24 A second
system uses Atg7, Atg3, and the Atg12–Atg5–Atg16L1 complex
(E1, E2, and E3 enzymes, respectively) to catalyze the addition of
phosphatidylethanolamine to the microtubule-associated protein
1A/B light chain 3 (LC3), producing LC3II.25,26 LC3II is attached to
both inner and outer autophagosome membranes,27 and thus is a
marker for isolation membranes (ie, phagophores), autophago-
somes, and autolysosomes. During maturation, autophagosomes
fuse with multivesicular bodies, late endosomes, and lysosomes,
forming acidic compartments in which LC3II on the inner auto-
phagosome membrane is degraded, along with the luminal contents.
This fusion process is mediated by syntaxin 17, SNAP29, VAMP3,
VAMP8, and Atg14/Atg14L.6,28-30
Although autophagy is important in nucleated cells, its role in
anucleate cells is less recognized. In the eye, deletion of Atg5 or Vps34,
althoughcausingcataracts, doesnot impair organelle clearance in the lens
organelle-free zone.31 The role of autophagy in differentiated anucleate
red blood cells is unclear, despite its importance for mitochondrial
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clearance during erythroid maturation.32-38 Autophagy in platelets
is understudied. Only recently, a role for autophagy in megakar-
yopoiesis and thrombopoiesis was indicated in a study on
hematopoietic lineage-specific Atg7 deletion mice carrying Vav
promoter-driven Cre.39 Feng et al reported starvation/rapamycin-
induced autophagy in platelets.40 They also found that platelets isolated
from whole-body heterozygous Becn1 knockout mice are defective in
ex vivo collagen-induced aggregation, as well as flow-based platelet
adhesion and thrombus formation.40 However, they did not detect
autophagy induction in response to platelet agonists, nor were
they able to distinguish the unique contribution of platelet autophagy
deficiency to hemostasis impairment, given Becn1-deficiency in
other cell types (eg, endothelial cells). Our studies extend these initial
observations and show that autophagy not only occurred consti-
tutively in resting platelets but also was induced during platelet
activation. We further show that megakaryocyte- and platelet-
specific deletion of Atg7 (using platelet factor 4 [PF4] promoter-
driven Cre) caused modest defects in platelet aggregation and
granule cargo packaging, but had a profound effect on hemostasis
and thrombosis, despite normal platelet counts and mean platelet
volumes. Our results demonstrate a critical role for autophagy in
platelet activation during hemostasis and thrombosis.
Method
Mouse strains
Animal procedures were approved by the Institutional Animal Care and Use
Committees at the relevant institutions. GFP-LC3/1mice, in which GFP-LC3
expression is controlled by an actin promoter, were obtained from Noboru
Mizushima (University of Tokyo, Japan).41,42 Becn1-EGFP/143 and EGFP-
Atg5/1 mice were generated using bacterial artificial chromosome (BAC)
transgenics.44 To make EGFP-Atg5/1mice, BAC clone (#RP24-117F24) con-
taining the entire mouse Atg5 gene was purchased from Children’s Hospital
OaklandResearch Institute (Oakland, CA). The sequence for EGFPwas inserted
after the Atg5 start codon, and the modified BAC was injected into B6C3 F1
hybrideggs at theMountSinaiSchoolofMedicine core facility (NewYork,NY).
GFP-LC3/1, Becn1-EGFP/1, and EGFP-Atg5/1mice were genotyped using
59- CCTACGGCGTGCAGTGCT TCAGC-39 (forward) and 59-CGGCGA
GCT GCA CGC TGC GTC CTC-39 (reverse).
VAMP82/2micewere describedpreviously.45Platelet-specificVAMP2/32/2
mice were generated by PF4-Cre-mediated46 expression of tetanus neurotoxin
endopeptidase,which cleaves bothVAMP2andVAMP3.47VAMP2/3/82/2mice
weregenerated fromVAMP2/32/2andVAMP82/2miceandwillbedescribedelse-
where. Atg7f/f;PF4-Cre/1 mice were generated by crossing Atg7f/f mice48 with
PF4-Cre mice.46 Floxed Atg7 alleles were genotyped using 59- TGG CTG CTA
CTTCTGCAATGATGT-39 (forward) and59-CAGGACAGAGACCATCAG
CTC CAC-39 (reverse). PF4-Cre was genotyped using 59-CCC ATA CAG CAC
ACC TTT TG-39 (forward) and 59-TGC ACA GTC AGCAGG TT-39 (reverse).
Ex vivo assays
Humanplateletswere prepared as described49 fromplatelet-rich plasma (obtained
from theKentuckyBloodCenter).Mouse plateletswere prepared as described.49
Blood was drawn via heart puncture into 0.38% (final) sodium citrate, diluted
(1:1) with Tyrode’s buffer (pH 6.5; 20 mM N-2-hydroxyethylpiperazine-N9-2-
ethanesulfonic acid/KOH, 128 mMNaCl, 2.8 mMKCl, 1 mMMgCl2, 5 mM
D-glucose, 12 mMNaHCO3, 0.4 mMNaH2PO4) containing 0.2U/mL apyrase
and 10 ng/mL PGI2 and separated at 215g for 10 minutes at room temperature.
Platelet-rich plasma was separated at 675g for 10 minutes. Platelet pellets were
resuspended in Tyrode’s buffer (pH 6.5) containing apyrase, PGI2, and 1 mM
EGTA. After washing, platelets were resuspended in Tyrode’s buffer (pH 7.4)
with 0.02 U/mL apyrase and 1 mM CaCl2. Platelet concentrations were mea-
sured using a Z2 Counter (Beckman Coulter, Miami, FL).
For western blot analysis, washed platelets (1.2 3 109/mL) were
preincubated with the indicated inhibitors and stimulated with the indicated
agonists. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis on 4% to 12% (or 12% for LC3) Bis-Tris gels (Invitrogen,
Grand Island, NY) before western blotting, using appropriate antibodies
(see the supplemental Methods, available on the Blood Web site). Films
were exposed for different periods to optimize signals. Images of films were
scanned in positive mode and analyzed using ImageJ (National Institutes of
Health).
Platelet aggregation and adenosine triphosphate release were measured with
washed platelets (2.53 108/mL), as described,45 in a Lumi-Dual Aggregometer
(Model 460VS) with Aggro/Link interface (Model 810) and software (Chrono-
Log, Havertown, PA).
Dense granule, a-granule, and lysosome secretion were assayed as
described.45,50-53 Specifically, PF4 was assessed by anti-PF4/CXCL4 ELISA,
[3H]-serotonin levels determinedby scintillation counting, andb-hexosaminidase
activity evaluated using a colorimetric assay.54 Total PF4 levels, total uptake
of [3H]-serotonin, and totalb-hexosaminidase activity were recorded, and the
percentage secretion was calculated.53
In vivo tail-bleeding assay
This assay was performed as described.55 To measure bleeding, tails of 5- to
6-week-old sedated (ketamine, 75mg/kg, intraperitoneally)micewere transected
3mmfrom the tip and immersed in saline at 37°C.The time required for bleeding
cessation was recorded, and the mice were observed for an additional minute.
Experiments were terminated at 10 minutes. The transected tail tips were used
for genotyping.
In vivo FeCl3-induced carotid injury model
This assay was performed as described.56 Mice at 21 to 32 weeks of age
were anesthetized with avertin (tribromoethanol; 200 mg/kg; intraperito-
neally). The left carotid artery was exposed and visualized through a dis-
sectingmicroscope.ADoppler,microvascular probewasplaced on the exposed
artery to measure vascular blood flow, and the artery was injured by placing
a small piece of filter paper saturated with 6% FeCl3 directly on the artery for
3minutes. Times to form stable, occlusive thrombi were recorded. Experiments
were terminated at 3minutes postocclusion or 30minutes postinjury,whichever
occurred first.
Platelet count and volume measurements
Mice were anesthetized with isoflurane, and blood (50;200 mL) was collected
from the retroorbital plexus into heparinized capillary tubes containing EDTA
(10 mM). Platelet counts and mean platelet volumes were analyzed with
a HEMAVET HV950FS analyzer (Drew Scientific, Waterbury, CT).
Results
Autophagy machinery is present in murine and human
platelets
Autophagy gene transcripts57,58 and proteins59-62 have been
detected in platelets. To confirm, we probed murine and human
platelet extracts with antibodies to autophagy-related proteins. We
detected components of the Ulk1 complex (eg, Ulk1 and FIP200),
the Atg12-Atg5 and LC3II conjugation systems (eg, Atg7, Atg3,
Atg12, Atg5, and LC3II), and the Beclin 1-Vps34 complex (eg,
Beclin 1, Vps34, Vps15, Atg14L,Nrbf2, andUVRAG) (Figure 1A;
supplemental Figure 1, summarized in supplemental Table 1). We
next examined platelets from transgenic mice expressing GFP-fused
autophagymarkers (LC3,41 Atg5, and Beclin 143) to visualize isolation
membranes, autophagosomes, and autolysosomes in resting platelets.
GFP-LC3, expressed at higher levels than endogenous LC3II
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(supplemental Figure 2, lane 2), displayed both diffuse and punctate
localizationpatterns (Figure 1B).EGFP-Atg5 andBeclin 1-EGFP, both
expressed at lower than endogenous protein levels (supplemental
Figure 2, lanes 3 and 4), were also localized to puncta (Figure 1B).
These data confirm the presence of the autophagymachinery inmurine
and human platelets and suggest that autophagosome-related structures
are present in resting platelets.
Basal autophagy occurs in resting platelets
To determinewhether basal autophagy occurred in resting platelets, we
monitored LC3II levels in unstimulated platelets in the presence or
absence of lysosomal inhibitors (eg, NH4Cl and chloroquine). Treat-
ment with NH4Cl and, less effectively, with chloroquine, increased
LC3II levels over time in unstimulated human platelets (Figure 2A).
Consistently, unstimulatedGFP-LC3/1platelets containingGFP-LC3-
positive puncta increased from 21 6 8% in the absence of NH4Cl to
64 6 10% in the presence of NH4Cl (Figure 2B; P , 10
27).
Together, thesefindings indicate the presence of a basal autophagicflux
(ie, turnover of autophagosomes) in resting platelets, which can be
inhibited by lysosomal inhibitors.
Because anucleate platelets have few means for transcription, we
asked whether translation contributed to basal autophagy, and thus
accounted for the changes in LC3II seen in lysosomal inhibitor-treated
resting platelets. Neither cycloheximide nor puromycin affected LC3II
levels, regardless ofwhether lysosomal proteolysis was inhibited or
not (Figure 2C). These results imply that in resting platelets, LC3II
and autophagosomes are continuously produced, independent of
LC3 translation.
Platelet activation leads to LC3II reduction and altered
autophagic flux
Given that autophagic flux appeared to occur in resting platelets, we
sought to determine whether it changed upon platelet activation. We
found that LC3II levels decreased in response to thrombin in both
murine and human platelets; this observation was confirmed using 4
different anti-LC3 antibodies (Figure 3A). We tested other platelet
agonists and found that LC3II levels in human platelets were reduced
by ;2.5-fold in response to strong activators (thrombin, convulxin
[CVX], and PAR1 peptide), whereas weaker activators (ADP, col-
lagen, and U46619) led to modest LC3II reduction (;1.5-fold)
(Figure 3B). Similar agonist-induced LC3II reductions were observed
in murine platelets (supplemental Figure 3). These results indicate that
platelet activation results in a loss of LC3II, indicating an alteration in
autophagic flux.
To delineate which platelet activation step or steps are required for
agonist-induced LC3II reduction and to determine whether autophagy
is downstream of the known platelet signaling cascades, we tested the
effects of platelet activation inhibitors on agonist-induced LC3II re-
duction. The phospholipase C inhibitor, U-73122, but not its inactive
analog, U-73343, blocked thrombin-induced LC3II reduction (Figure
3C). The permeant calcium chelator BAPTA-AM and the protein
kinase C inhibitor Ro-31-8220 also blocked thrombin-induced LC3II
reduction (Figure 3C). In addition, PP2, the inhibitor of Src-family
tyrosine kinases, blocked CVX-induced LC3II reduction (Figure 3C).
Together, our results demonstrate that platelet agonists induce LC3II
reduction, which requires known elements of platelet activation sig-
naling cascades; for example, phospholipaseC,Ca21, protein kinaseC,
and Src-family kinases.
Figure 1. Autophagy machinery is present in murine
and human platelets. (A) Western blot analyses of the
autophagy machinery in freshly prepared mouse and
human platelets and in banked human platelets. Ex-
tracts from mouse and human platelets were loaded
in each lane and probed with antibodies to the indi-
cated proteins. Atg51/1 and Atg52/2mouse embryonic
fibroblasts (MEFs) were used as additional molecu-
lar weight markers for LC3I (unconjugated form) and
LC3II (phosphatidylethanolamine-conjugated form), as
Atg52 /2 MEFs produced LC3I but not the faster-
migrating LC3II. Atg52/2 MEFs also had higher p62
levels than Atg51/1 MEFs because of impaired auto-
phagy. Note that the loading amounts for the MEFs
were much lower than those for platelets to have
comparable LC3II levels. As a result, and as platelets
have high actin content than the MEFs, both actin and
p62 levels in the MEF samples are much lower than in
platelets. The images shown are representative of at
least 3 independent experiments. Full images of all
blots are shown in supplemental Figure 1. (B) Platelets
from the autophagy reporter mice (ie, GFP-LC3/1,
Becn1-EGFP/1, EGFP-Atg5/1) but not wild-type mice
show GFP-LC3-positive, EGFP-Atg5-positive, and Beclin
1-EGFP-positive puncta, respectively (arrows), which
are autophagosome-related structures including iso-
lation membranes, autophagosomes, and autolyso-
somes. Samples were visualized for GFP or EGFP
fluorescence (fluorescein isothiocyanate [FITC] channel)
and differential interference (DIC). The images shown
are representative of at least 2 independent experiments.
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Agonist-induced LC3II reduction involves
autolysosomal proteolysis
To determine whether agonist-induced LC3II reduction involved
proteolysis, we preincubated human platelets with a protease
inhibitor cocktail (PIC) before stimulation. The PIC pretreatment
blocked thrombin-, PAR1-, and CVX-induced LC3II reduction in
platelets (Figure 4A). Although inhibition of thrombin-induced
reduction in LC3II could be attributed to a direct effect of serine
protease inhibitors in the PIC on thrombin, inhibition of PAR1- and
CVX-induced LC3II reduction was likely a result of inhibition of
proteolysis unrelated to thrombin. The ubiquitin–proteasome sys-
tem and autophagy are 2 major degradation pathways in eukary-
otes. The ubiquitin–proteasome system has been reported to be
important for thrombopoiesis and platelet function.63,64 We asked
whether agonist-induced LC3II reduction involved proteasomes.
Inhibition of proteasomeswithMG132had no effect onCVX-induced
LC3II reduction in mouse platelets (supplemental Figure 4A),
Figure 2. Basal autophagy occurs in resting plate-
lets. (A) Western blot analysis of LC3II in unstimulated
human platelets treated with either NH4Cl (20 mM) or
chloroquine (50 mM) to inhibit lysosomal activity. Two
exposure times, short and long, are shown. Note that
LC3I is visible only with longer exposures in this ex-
periment. (B) GFP-LC3 puncta in unstimulated plate-
lets without and with NH4Cl treatment (20 mM, 2 h).
Samples were visualized for DIC and GFP fluores-
cence (GFP-LC3). Ten images (17;74 platelets/field)
were obtained at random and quantified for
each condition. Platelets containing GFP-LC3-positive
puncta are 21 6 8% and 64 6 10% without and with
NH4Cl treatment, respectively. Statistical significance
was evaluated with the Student t test. (C) Western blot
analysis of LC3II in human platelets pretreated for 1 h
with cycloheximide (100 mg/mL) or puromycin (10 mg/mL),
in combination with pretreatment of NH4Cl (20 mM, 1 h)
or protease inhibitor cocktail (1 h). The images shown
are representative of at least 3 independent experiments.
Figure 3. Platelet activation leads to LC3II re-
duction. (A) Western blot analysis of LC3II in the
murine and human platelets before and after stimula-
tion (0.1 U/mL thrombin, 30 minutes), with various anti-
LC3 antibodies. Cell extracts from Atg51/1 and Atg52/2
MEFs were used as additional molecular weight markers
to indicate the migration positions of LC3I and LC3II.
Note that the loading volumes for the MEFs were
optimized to have comparable LC3II levels, and platelets
have high actin content. Thus, both actin and p62 levels
in the MEF samples were below detection limits. The
images shown are representative of at least 2 independent
experiments. (B) Western blot analyses of LC3II in human
platelets before and after stimulation with various agonists.
Platelets were stimulated for 30 minutes with thrombin
(0.1 U/mL), CVX (0.1 mg/mL), PAR1 or PAR4 peptide
(100 mM), ADPbS (10 mM), collagen (1 mg/mL), A23187
(10 mM in DMSO), and U46619 (20 mM in DMSO).
N 5 2;8 for various inhibitors. (C) Western blot analysis
of LC3II, before and after stimulation, in human platelets
pretreated with inhibitors of platelet activation. Platelets
were pretreated for 60 minutes with U-73122 (20 mM),
U-73343 (inactive analog of U-73122, 20 mM), BAPTA-AM
(100 mM), Ro-31-8220 (10 mM), or PP2 (100 mM)
and then stimulated for 30 minutes with either thrombin
(0.1 U/ml) or CVX (0.1 mg/mL). Of note, U-73343, Ro-
31-8220, and PP2 increased LC3II levels in resting
platelets for an unknown reason. All inhibitor stock solutions
were prepared in DMSO. N5 3 for all inhibitors. For B and
C, *P , .05 by the Student t test.
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suggesting agonist-induced LC3II degradation is not a result of
proteasomal activity. In contrast, treatment of mouse platelets with
NH4Cl to neutralize lysosomal pH suppressed thrombin-induced
LC3II reduction (Figure 4B), suggesting active proteolysis in acidic
compartments contributes to agonist-induced LC3II reduction.
In nucleated cells, proteolysis of LC3II requires autophagosome–
lysosome fusion. To determine whether this is also required for
agonist-induced LC3II reduction in platelets, we examined platelets
from mice with defective membrane fusion machinery. Platelets
lacking 3 of the 4 major VAMPs (ie, VAMP2/3/82/2) showed greatly
impaired thrombin-induced LC3II reduction, whereas those deficient
in either VAMP2/VAMP3 or VAMP8 showed no overt impairment
(Figure 4C). These results suggest that VAMP2, VAMP3, and
VAMP8have redundant function in agonist-induced autophagosome–
lysosome fusion.Notably, the resting platelets purified fromVAMP82/2,
VAMP2/32/2, and VAMP2/3/82/2 mice had increased LC3II levels
relative to control platelets, which expressed normal levels of VAMP2,
VAMP3, and VAMP8, with VAMP2/3/82/2 platelets having the
highest LC3II levels (Figure 4C). This is consistent with VAMP-
mediated autophagosome–lysosome fusion being required for basal
autophagy in resting platelets. Together, our results suggest that
agonist-induced LC3II reduction likely results from platelet autolyso-
somal proteolysis; that is, canonical degradative autophagy is induced
upon platelet activation.
Of note, a new role of autophagy in unconventional secretion is
emerging recently.65We askedwhether exocytosis of LC3II-decorated
exosomes occurred upon agonist stimulation. We activated mouse
platelets with CVX, PAR4 peptide, or thrombin before separating
platelet-containing pellets from releasate-containing supernatants. PF4,
a known a-granule cargo, was the releasate control. Despite the ap-
pearanceofPF4,LC3IIwasnot detected in the supernatants of activated
platelets (supplemental Figure 4B), suggesting the absence of agonist-
induced exocytosis of LC3II-decorated exosomes.
Atg7-deficient platelets are defective in ex vivo platelet
aggregation and granule cargo packaging
Given the observed effects activation exerted on autophagy, we asked
whether platelet autophagyhad a functional role.Wegeneratedamouse
strain with a megakaryocyte- and platelet-specific deletion of Atg7 (ie,
Atg7f/f;PF4-Cre/1). Although Atg7 levels were only partially reduced
in platelets from Atg7f/f;PF4-Cre/1mice, LC3II was largely depleted
(Figure 5A), suggesting Atg7 is likely the rate-limiting enzyme for
LC3II production. We then systematically characterized platelets from
these Atg7-deficient mice, using standard ex vivo assays. First, we
monitored platelet aggregation by lumi-aggregometry and found that
Atg7 deficiency causeddefects in aggregation in response tomodest-to-
low concentrations of thrombin and collagen (Figure 5B). Second, we
assayed thrombin-dependent platelet exocytosis by monitoring
secretion of PF4 from a-granules, [3H]-serotonin from dense granules,
and b-hexosaminidase from lysosomes. Our data show that the total
levels of a-granule cargo PF4, the total uptake of [3H]-serotonin into
densegranules, and the total lysosomalb-hexosaminidaseactivitywere
slightly, but significantly, reduced in platelets from Atg7f/f;PF4-Cre/1
mice (by 15%, 26%, and 18%, respectively; P , .05), suggesting
modestly impaired granule cargo packing (Figure 5C). However, Atg7
deficiency did not impair percentage release of PF4, [3H]-serotonin,
or b-hexosaminidase (supplemental Figure 5A). Consistently, we also
found no overt alterations in the levels of the fusion machinery (eg,
STX11, SNAP23, VAMP3, and VAMP8) and the a-granule cargo
von Willebrand factor (supplemental Figure 5B). Third, to determine
the cause of the observed granule cargo packaging defects, we assessed
overall morphology of Atg7f/f and Atg7f/f;PF4-Cre/1 platelets by
electron microscopy. Our micrographs show that Atg7-proficient
platelets (Figure 5Di-iii) and Atg7-deficient platelets (Figure 5Div-vi)
had no overt difference in morphology. Of note, we observed isolation
membranes in platelets (Figure 5Dii-iii, arrowheads and inset). Fourth,
we examined integrin inside-out and outside-in signaling and found
that Atg7 deficiency had no effect on activation-dependent Jon/A
(supplemental Figure 5C) or fibrinogen (data not shown) binding,
platelet spreading (data not shown), or clot retraction (either in the
absence or presence of glucose; supplemental Figure 5D). In sum-
mary, we detected modest aggregation and granule cargo packag-
ing defects, but normal cargo release and integrin signaling in the
Atg7f/f;PF4-Cre/1 platelets.
Deletion of Atg7 in platelets leads to impaired hemostasis and
thrombus formation
Aswe observed defects in the Atg7-deficient platelets ex vivo, we next
determined the consequence of deletingAtg7 in platelets in vivo. Using
Figure 4. Agonist-induced LC3II reduction involves autolysosomal proteolysis.
(A) Western blot analysis of LC3II changes in response to agonists in banked human
platelets pretreated with a PIC. Platelets were incubated with the PIC for 60 minutes
before 30-minute agonist stimulation with thrombin (0.1 U/mL), PAR1 peptide (100 mM),
and CVX (0.1 mg/mL), respectively. The images shown are representative of at least
3 independent experiments. (B) Western blot analysis of LC3II in thrombin-stimulated
(0.1 U/mL, 30 minutes) mouse platelets after preincubation with NH4Cl (20 mM,
2 hours). The images shown are representative of 4 independent experiments. *P, .05.
(C) Western blot analysis of LC3II in thrombin-stimulated (0.1 U/mL, 30 minutes)
platelets isolated from mice lacking VAMP2, VAMP3, and/or VAMP8, and from
wild-type control mice. The images shown are representative of 2 independent
experiments.
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the tail-bleeding assay for hemostasis, we showed that 11 (;65%) of
17 of Atg7f/f;PF4-Cre/1 mice were unable to stop bleeding within
10minutes after tail transection,whereasAtg7f/f littermatesdemonstrated
normal bleeding time (median, ;2.5 minutes) (Figure 6A). Moreover,
using the FeCl3-induced carotid injury model, we further showed that
7 (;47%) of 15 of Atg7f/f;PF4-Cre/1 mice were unable to form
occlusive thrombi within 30 minutes after injury, whereas all Atg7f/f
littermates could do so (median occlusion time, ;5.6 minutes)
(Figure 6B). Of note, the occlusion times of Atg7f/f;PF4-Cre/1 mice
appeared to show a bimodal distribution for an unknown reason
(Figure 6B). BecausePF4-Cre expression deletes the floxedAtg7 gene
at a later stage of megakaryocyte differentiation,46 it is possible that
bleeding in Atg7f/f;PF4-Cre/1 mice is a result of defective platelet
production, especially given the thrombocytopenia phenotype of the
Atg7f/f;Vav-Cre/1 mice, where Atg7 is deleted at an earlier stage of
the hematopoietic cell lineage.39 To investigate this possibility, we
measured platelet counts and mean platelet volumes as metrics of
thrombocytopenia and faulty platelet production.ComparedwithAtg7f/f
mice, Atg7f/f;PF4-Cre/1 mice had indistinguishable platelet counts
(Figure 6C) and mean platelet volumes (Figure 6D), suggesting that
defects in Atg7-mediated platelet function or functions, but not throm-
bocytopenia, accounted for the severe bleeding in Atg7f/f;PF4-Cre/1
mice. Together, our results show that even partial reduction of Atg7
protein levels in Atg7f/f;PF4-Cre/1 platelets profoundly impairs hemo-
stasis and thrombus formation. As both LC3II depletion and impaired
hemostasis and thrombus formationwere observed inAtg7f/f;PF4-Cre/1
platelets, our results suggest that Atg7 may be a rate-limiting fac-
tor in the role that platelet autophagy plays during hemostasis and
thrombosis.
Discussion
Although autophagy-related mRNAs and proteins have been reported
in transcriptomic57,58 and proteomic59-62 studies, the functional rami-
fications of autophagy in platelets have only recently begun to be
addressed.39,40 Here we confirm the presence of many autophagy-
related proteins in platelets.Using transgenicmice expressingGFP-fused
LC3, Beclin 1, and Atg5, we further show that these autophagy markers
Figure 5. Atg7-deficient platelets showed modest defects in ex vivo platelet function assays. (A) Representative western blot analysis showing reduced Atg7 and
depleted LC3II levels in platelets from Atg7f/f;PF4-Cre/1mice compared with platelets from Atg7f/f mice. For each genotype, results from 2 different mice are shown. (B) Lumi-
aggregometry measurements of platelets from Atg7f/f (red traces) and Atg7f/f;PF4-Cre/1 (blue traces) mice when stimulated with thrombin (upper) or collagen (lower).
Different agonist concentrations were titrated. The images shown are representative of at least 3 independent experiments. (C) Total levels of PF4 (left), total [3H]-serotonin
uptake (middle), and total b-hexosaminidase activity (right) in platelets purified from Atg7f/f and Atg7f/f;PF4-Cre/1 mice. Data represent an average of 21 measurements.
*P, .05, **P, .001, Student t test. (D) EM images of platelets from Atg7f/f (i-iii) and Atg7f/f;PF4-Cre/1 (iv-vi) mice. Samples were prepared by the freeze substitution method.
a, a granules; arrows, dense granules; arrowheads and inset, isolation membranes. Scale bars, 500 nm. The images shown are representative micrographs from
2 independent experiments.
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are localized to punctate structures in platelets. We demonstrate that
autophagic flux occurs in resting platelets and is enhanced in response to
variousplatelet agonists.UsingmicewithPF4-Cre-driven,megakarcyte/
platelet-specific Atg7 deletion, we further show that platelet autophagy
contributes to hemostasis and thrombus formation. Collectively, our data
demonstrate physiological relevance of autophagy in platelets and add
autophagy to a growing list of cellular processes (eg, translation, secre-
tion, cytoskeletal rearrangements) that are unexpectedly important for
platelet functions.
Feng et al reported that platelet autophagy was independent of
activation.40 We tested several anti-LC3 antibodies, including the one
used by Feng et al (ie, Sigma L7543). All but the L7543 antibody de-
tected thrombin-induced LC3II reduction in both human and murine
platelets; even the L7543 antibody detected thrombin-induced LC3II
reduction in human platelets. We postulate that the L7543 antibody
may recognize a subpopulation of mouse LC3II that is less affected
by platelet activation. As LC3II reduction could result from decreased
biogenesis, increased degradation, or both, a standard assay for evalu-
ating autophagic flux is to monitor changes in LC3II levels in the
absence vs presence of lysosomal inhibitors.66,67 Using NH4Cl, we
confirmed agonist-induced LC3II reduction as a readout for agonist-
induced enhancement of autophagic flux. Other potential metrics of
autophagic flux, however, appear to be inappropriate for monitoring
platelet activation-induced autophagy. A classical autophagic flux
assay measures the long-lived protein degradation rates through pulse-
chase labeling. This assay is not applicable to platelets, as chase time
may exceed the time during which cultured platelets are fully fun-
ctional. The levels of p62, an adaptor protein that delivers substrates to
autophagosomes and is itself degraded in autolysosomes,68 have also
been used as indicators of autophagic flux in certain cell types.18,69,70
However, p62 did not accumulate in Atg7-deficient platelets
(supplemental Figure 5B). As p62 is one of many adaptors that bring
selected cargoes to autophagosomes, we cannot rule out the possibility
that agonist-induced platelet autophagy uses adaptors other than
p62. Together, our work establishes agonist-induced LC3II reduc-
tion as a useful measure for platelet activation-induced autophagy.
To our knowledge, this is the first report of autophagy induction
by platelet activation.
Deleting Atg7 early in platelet production by Vav-Cre39 or
prolonged platelet proteasome inhibition by genetic means63 have
been shown to cause abnormal megakaryopoiesis or thrombopoi-
esis, suggesting key degradation processes may be needed for pro-
per thrombocytogenesis. In contrast, although PF4-Cre-driven
Atg7 deletion caused severe hemostasis and thrombosis defects,
Atg7f/f;PF4-Cre/1 mice showed normal platelet counts, mean
platelet volumes, and ultrastructure (Figures 6C-D and 5D, respec-
tively), indicating proper platelet production. Thus, the use of the
PF4-Cre system allows us to examine the effects of autophagy
deficiency on platelets and hemostasis without the complication of
deficient platelet production.
The use of PF4-Cre also allows us to examine the effects of
autophagy deficiency on platelets and hemostasis without the com-
plication caused by lack of autophagy in other cell types. The bleed-
ing phenotype reported by Feng et al, in a global heterozygous
Becn1 mouse,40 is likely the culmination of Beclin 1 depletion in
several cell types; for example, endothelial cells and platelets. Con-
sistently, other studies have shown that loss of autophagy in en-
dothelial cells, although it causes no abnormality in platelets,
decreases secretion of von Willebrand factor, prolongs thrombus
formation times, and yields smaller thrombi.71,72 Our work is the
first direct report of platelet autophagy being essential for hemo-
stasis and thrombosis. Our work clearly demonstrates that platelet
Atg7 is indispensable and likely a rate-limiting factor for platelet
autophagy’s role in hemostasis and thrombosis. This is confirmed
Figure 6. Megakaryocyte- and platelet-specific Atg7
deletion causes impaired hemostasis and thrombus
formation without thrombocytopenia. (A) Tail-bleeding
time measurements taken from Atg7f/f (s) and Atg7f/f;
PF4-Cre/1 (filled gray triangles) mice. (B) Occlusion
time measurements taken from Atg7f/f (s) and Atg7f/f;
PF4-Cre/1 (filled gray triangles) mice in the FeCl3
carotid injury model of thrombosis. For A and B, each
data point represents an individual mouse, with the
horizontal line marking the median. Statistical signifi-
cance was evaluated with the log-rank test using
SigmaPlot12 software. (C) Platelet counts and (D) mean
platelet volumes from Atg7f/f (s) and Atg7f/f;PF4-Cre/1
(filled gray triangles) mice. For C and D, statistical
significance was evaluated with the Student t test. NS,
not significant.
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by our unpublished data showing similar bleeding diatheses in
mice with megakaryocyte/platelet-specific deletion of other key
autophagy genes; for example, Becn1f/f;PF4-Cre/1 and Pik3c3f/f;
PF4-Cre/1 (data not shown).
Despite robust in vivo phenotypes, megakaryocyte/platelet-
specific Atg7 deficiency only modestly affected aggregation and
granule cargo packaging and had limited effects on cargo release
or integrin signaling. We performed additional ex vivo platelet
assays to examine effects of platelet Atg7 loss on phosphatidylser-
ine (PS) exposure and energetics. Both Atg5 and Beclin 1 are
essential for apoptotic cell clearance during development by
mediating expression of extracellular PS.73 As PS exposure is also
important for hemostasis,74,75 we thought that autophagy-mediated
PS exposure in platelets might be required for hemostasis.
Unfortunately, this hypothesis is unlikely, as our studies with
annexinV (data not shown) and lactadherin (supplemental Figure 5E)
binding showed no impairment in activation-dependent PS exposure
on Atg7f/f;PF4-Cre/1 platelets. As the conventional role of auto-
phagy is for adenosine triphosphate production and nutrient
recycling through catabolism, and autophagy is essential for the
clearance of damaged organelles such as mitochondria, we speculated
that platelet autophagy may be critical for energetics. However,
there was no clot retraction defect observed in the Atg7-deficient
platelets, even when glucose was withheld (supplemental Figure 5D),
suggesting Atg7-deficiency does not impair glucose use in platelets.
At this stage, we have insufficient data to define the mechanism
by which Atg7-deficient mice demonstrate severe hemostasis and
thrombosis defects. There are ample published examples in which
deletion of a signaling cascade protein causes only modest defects
in platelet activation in ex vivo assays, yet the protein contributes
significantly to in vivo hemostasis and thrombosis.56,76-79 In a re-
cent example, STXBP5 deletion yielded modest defects on dense
granule release but was absolutely required for hemostasis in the
tail transection model and for thrombosis in the FeCl3-induced
carotid injury model.80 Therefore, it is possible that the sensitivity
of the ex vivo assays we employed are insufficient to fully delineate
the effects of deleting the autophagy machinery. There may be an
additive or even synergistic effect resulting from several singularly
mild impairments.
Alternatively, it is possible that autophagy deficiency may cause
some unidentified platelet dysfunction, leading to the observed severe
hemostasis and thrombosis defects. Our current hypothesis is that
platelet autophagy-mediated degradation of a specific substrate or
substrates is required for effective hemostasis and thrombosis. Con-
sistent with this concept, there are functional similarities between the
2 major degradation systems: the ubiquitin–proteasome system and
autophagy in platelets. Both occur in resting platelets and are activated
upon stimulation64,81-83 (Figures 2-4), and both are needed for occlu-
sive thrombus formation after FeCl3 injury
64 (Figure 6B). In addition,
the severity of the hemostasis and thrombosis defects caused by
inhibiting either proteasome or autophagy exceed the expectation
for modest defects based on ex vivo assay phenotypes. This implies
that some degradative processes must occur in situ, in the growing
thrombi for effective hemostasis and thrombosis. For the protea-
some, some of the important targets have been identified; for
example, filamin, talin, and Syk.64,84 For autophagy, the substrates
are unknown. Proteomic analysis of extracts and releasates from
autophagy-deficient platelets will be required to test this hypoth-
esis. In short, our data and those of others clearly demonstrate that
some regulated degradation steps are important for platelet function.
What remains is to determine what targets must be degraded and why
their removal is important.
Note in added proof. While this manuscript was under review,
a case report was published illustrating autophagosome-like structures
in platelets from a dog with severe nonregenerative anemia.85
Moreover, another work using hematopoietic system conditional
Atg7 knockout (ie, Atg7f/f;Vav-Cre) mice was published that dem-
onstrates that in addition to severe defects in megakaryogenesis,
megakaryocyte differentiation and thrombopoiesis observed in these
mice, platelets isolated from these mice are defective in activation and
aggregation.39 Our work using Atg7f/f;PF4-Cre mice, which deletes
the Atg7 genes at a later stage in platelet production, distinguishes the
roles of autophagy in platelets and in hemostasis from roles in
megakaryogenesis and in megakaryocyte differentiation.
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